Azevan Pharmaceuticals Overview

  • Year Founded
  • 1999

Year Founded

  • Status
  • Private

  • Latest Deal Type
  • Grant

  • Latest Deal Amount
  • $11.6M

  • Investors
  • 9

Azevan Pharmaceuticals General Information

Description

Developer of novel therapeutics designed to treat disorders of stress, mood, and behavior. The company's medicines selectively block the effects of arginine vasopressin, a peptide neurohormone involved in the pathophysiology of intermittent explosive disorder, neuropsychiatric symptoms in neurodegenerative diseases, PTSD, and other affective disorders, enabling physicians to treat patients suffering from neurodegenerative diseases effectively.

Contact Information

Website
www.azevan.com
Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Corporate Office
  • 116 Research Drive
  • Bethlehem, PA 18015
  • United States
+1 (610)
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Vertical(s)
Corporate Office
  • 116 Research Drive
  • Bethlehem, PA 18015
  • United States
+1 (610)

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Azevan Pharmaceuticals Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
5. Grant 01-Jan-2019 $11.6M Completed Clinical Trials - Phase 2
4. Grant 01-Sep-2015 Completed Clinical Trials - Phase 2
3. Later Stage VC (Series C) 17-Jul-2015 Completed Clinical Trials - Phase 2
2. Later Stage VC (Series B) 10-Mar-2009 $4.09M $8.34M Completed Clinical Trials - Phase 2
1. Later Stage VC (Series A) 20-Jul-2005 $4.25M $4.25M Completed Clinical Trials - Phase 2
To view Azevan Pharmaceuticals’s complete valuation and funding history, request access »

Azevan Pharmaceuticals Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion Price % Owned
Series C-1
Series C
Series B 6,000,000 $0.001000 8% $1.32 $1.32 1x $1.32 33.86%
Series A 6,500,000 $0.001000 8% $1 $1 1x $1 36.68%
To view Azevan Pharmaceuticals’s complete cap table history, request access »

Azevan Pharmaceuticals Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Developer of novel therapeutics designed to treat disorders of stress, mood, and behavior. The company's medicines selec
Drug Discovery
Bethlehem, PA

Barcelona, Spain
 

Boston, MA
 
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Azevan Pharmaceuticals Competitors (13)

One of Azevan Pharmaceuticals’s 13 competitors is Ona Therapeutics, a Venture Capital-Backed company based in Barcelona, Spain.

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Ona Therapeutics Venture Capital-Backed Barcelona, Spain
Avalyn Pharma Formerly VC-backed Boston, MA
Cardurion Venture Capital-Backed Burlington, MA
Gesynta Pharma Venture Capital-Backed Stockholm, Sweden
Volastra Venture Capital-Backed New York, NY
You’re viewing 5 of 13 competitors. Get the full list »

Azevan Pharmaceuticals Patents

Azevan Pharmaceuticals Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
AU-2018333051-A1 Compositions and methods for treating brain injury Active 15-Sep-2017
AU-2018333051-B2 Compositions and methods for treating brain injury Active 15-Sep-2017
CA-3075759-A1 Compositions and methods for treating brain injury Pending 15-Sep-2017
EP-3681871-A1 Compositions and methods for treating brain injury Pending 15-Sep-2017
EP-3681871-A4 Compositions and methods for treating brain injury Pending 15-Sep-2017 A61K31/496
To view Azevan Pharmaceuticals’s complete patent history, request access »

Azevan Pharmaceuticals Investors (9)

Investor Name Investor Type Holding Investor Since Participating Rounds
Eunice Kennedy Shriver National Institute of Child Health and Human Development Government
National Institute of Mental Health Government
National Institutes of Neurological Disorders and Stroke Government
AG Hill Partners Family Office Minority
Scientific Health Development Venture Capital Minority
You’re viewing 5 of 9 investors. Get the full list »

Azevan Pharmaceuticals FAQs

  • When was Azevan Pharmaceuticals founded?

    Azevan Pharmaceuticals was founded in 1999.

  • Where is Azevan Pharmaceuticals headquartered?

    Azevan Pharmaceuticals is headquartered in Bethlehem, PA.

  • What industry is Azevan Pharmaceuticals in?

    Azevan Pharmaceuticals’s primary industry is Drug Discovery.

  • Is Azevan Pharmaceuticals a private or public company?

    Azevan Pharmaceuticals is a Private company.

  • What is Azevan Pharmaceuticals’s current revenue?

    The current revenue for Azevan Pharmaceuticals is .

  • How much funding has Azevan Pharmaceuticals raised over time?

    Azevan Pharmaceuticals has raised $10.8M.

  • Who are Azevan Pharmaceuticals’s investors?

    Eunice Kennedy Shriver National Institute of Child Health and Human Development, National Institute of Mental Health, National Institutes of Neurological Disorders and Stroke, AG Hill Partners, and Scientific Health Development are 5 of 9 investors who have invested in Azevan Pharmaceuticals.

  • Who are Azevan Pharmaceuticals’s competitors?

    Ona Therapeutics, Avalyn Pharma, Cardurion, Gesynta Pharma, and Volastra are some of the 13 competitors of Azevan Pharmaceuticals.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process